IPI Legacy Liquidation Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
118
- Latest Deal Type
-
M&A
- Investors
-
1
IPI Legacy Liquidation General Information
Description
IPI Legacy Liquidation Co formerly Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.
Contact Information
Website
www.impelpharma.com(Operating Subsidiary)
Corporate Office
- 201 Elliott Avenue West
- Suite 260
- Seattle, WA 98119
- United States
Corporate Office
- 201 Elliott Avenue West
- Suite 260
- Seattle, WA 98119
- United States
IPI Legacy Liquidation Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 27. Merger/Acquisition | 12-Feb-2024 | Completed | Generating Revenue | |||
| 26. Bankruptcy: Admin/Reorg | 19-Dec-2023 | Completed | Bankruptcy: Admin/Reorg | |||
| 25. General Corporate Purpose | 21-Aug-2023 | Completed | Clinical Trials - Phase 3 | |||
| 24. General Corporate Purpose | 17-Mar-2022 | Completed | Clinical Trials - Phase 3 | |||
| 23. 2PO | 10-Sep-2021 | Completed | Clinical Trials - Phase 3 | |||
| 22. Debt Refinancing | 06-Jul-2021 | Completed | Clinical Trials - Phase 3 | |||
| 21. IPO | 22-Apr-2021 | Completed | Clinical Trials - Phase 3 | |||
| 20. Later Stage VC | 12-Mar-2021 | Completed | Clinical Trials - Phase 3 | |||
| 19. Debt - General | 05-Nov-2020 | $30M | $154M | Completed | Clinical Trials - Phase 3 | |
| 18. Secondary Transaction - Private | $124M | Completed | Clinical Trials - Phase 3 |
IPI Legacy Liquidation Comparisons
Industry
Financing
Details
IPI Legacy Liquidation Competitors (47)
One of IPI Legacy Liquidation’s 47 competitors is Curemark, a Venture Capital-Backed company based in New York, NY.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Curemark | Venture Capital-Backed | New York, NY | ||||
| 4D Molecular Therapeutics | Formerly VC-backed | Emeryville, CA | ||||
| Ionis Pharmaceuticals | Corporate Backed or Acquired | Carlsbad, CA | ||||
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA |
IPI Legacy Liquidation Patents
IPI Legacy Liquidation Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021207626-A1 | Repeated administration of dihydroergotamine for treatment of frequent migraine headaches | Inactive | 14-Jan-2020 | ||
| AU-2021207626-A8 | Repeated administration of dihydroergotamine for treatment of frequent migraine headaches | Inactive | 14-Jan-2020 | ||
| CA-3167555-A1 | Repeated administration of dihydroergotamine for treatment of frequent migraine headaches | Pending | 14-Jan-2020 | ||
| EP-4090331-A1 | Repeated administration of dihydroergotamine for treatment of frequent migraine headaches | Inactive | 14-Jan-2020 | ||
| EP-4090331-A4 | Repeated administration of dihydroergotamine for treatment of frequent migraine headaches | Inactive | 14-Jan-2020 | A61K31/4985 |
IPI Legacy Liquidation Signals
IPI Legacy Liquidation Former Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 3M Ventures | Corporate Venture Capital | Minority | ||
| 5AM Ventures | Venture Capital | Minority | ||
| Alliance of Angels | Angel Group | Minority | ||
| Atlas Accelerator | Venture Capital | Minority | ||
| Cowles Ventures | Family Office | Minority |
IPI Legacy Liquidation ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
IPI Legacy Liquidation FAQs
-
When was IPI Legacy Liquidation founded?
IPI Legacy Liquidation was founded in 2008.
-
Where is IPI Legacy Liquidation headquartered?
IPI Legacy Liquidation is headquartered in Seattle, WA.
-
What is the size of IPI Legacy Liquidation?
IPI Legacy Liquidation has 118 total employees.
-
What industry is IPI Legacy Liquidation in?
IPI Legacy Liquidation’s primary industry is Drug Discovery.
-
Is IPI Legacy Liquidation a private or public company?
IPI Legacy Liquidation is a Private company.
-
What is IPI Legacy Liquidation’s current revenue?
The current revenue for IPI Legacy Liquidation is .
-
How much funding has IPI Legacy Liquidation raised over time?
IPI Legacy Liquidation has raised $348M.
-
Who are IPI Legacy Liquidation’s investors?
3M Ventures, 5AM Ventures, Alliance of Angels, Atlas Accelerator, and Cowles Ventures are 5 of 18 investors who have invested in IPI Legacy Liquidation.
-
Who are IPI Legacy Liquidation’s competitors?
Curemark, 4D Molecular Therapeutics, Ionis Pharmaceuticals, Merck & Co., and Alnylam Pharmaceuticals are some of the 47 competitors of IPI Legacy Liquidation.
-
When was IPI Legacy Liquidation acquired?
IPI Legacy Liquidation was acquired on 12-Feb-2024.
-
Who acquired IPI Legacy Liquidation?
IPI Legacy Liquidation was acquired by Woodward Pharma Services.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process